Gary Kelloff, M.D.

Gary Kelloff, M.D.

Gary J. Kelloff, MD has had over 40 years in cancer research at the National Cancer Institute (NCI), authoring more than 400 publications. Dr. Kelloff is a graduate of the University of Colorado (BS and MD degrees). After post-graduate training in medicine at Emory University, he began his NCI career as an intramural scientist and section head in viral immunology working on retroviruses and oncogenes.

Eric Kaldjian, M.D.

Eric Kaldjian, M.D.

Eric Kaldjian, M.D., has been Medical Director, Companion and Translational Diagnostics at Ventana Medical Systems (Roche Tissue Diagnostics), since June, 2012, He is the medical lead for the Companion Diagnostics Lifecycle and heads the CAP/CLIA team of pathologists that provide pathology services for translational diagnostics studies and for the assay development laboratory.

Lynn D. Hudson, Ph.D.

Lynn D. Hudson, Ph.D.

Dr. Lynn Hudson serves as the Chief Science Officer for the Critical Path Institute (C-Path) and Executive Director of the Multiple Sclerosis Outcome Assessments Consortium. She started at C-Path by overseeing the first regulatory qualification of an imaging biomarker for patient enrichment in clinical trials for Alzheimer’s disease.  Lynn graduated with a B.S. in Biochemistry from the University of Wisconsin and a Ph.D.

Andy Hospodor, Ph.D.

Andy Hospodor, Ph.D.

Dr. Hospodor has worked for IBM, Quantum (now Maxtor), and Western Digital, among other companies, since receiving his PhD degree from Santa Clara University. His research interests include interconnection network architectures for storage systems and scalable storage for computational grids.

In addition to researching Shingled Write Disks within the SSRC, Dr. Hospodor is the Executive Director of the SSRC, and is helping to deepen the connections between the SSRC and industry.

Laura Heiser, Ph.D.

Laura Heiser, Ph.D.

Dr. Heiser is a Research Assistant Professor at Oregon Health and Science University. Dr. Heiser studied molecular biology at the University of California, Berkeley (1998), and earned her Ph.D. in neuroscience from the University of Pittsburgh in 2007. She completed postdoctoral studies under the direction of Paul Spellman and Joe Gray at Lawrence Berkeley National Laboratory. Her research focuses on the genomic and epigenomic changes that drive oncogenic behavior in breast cancer, with the goal of identifying aberrations and pathways associated with therapeutic response and resistance.

Timothy J.R. Harris, Ph.D., D.Sc.

Timothy J.R. Harris, Ph.D., D.Sc.

Founder and Scientific Advisor, is currently the Senior Vice President of Translational Medicine at Biogen Idec in Cambridge, MA. Previously he was CTO and Director of the Advanced Technology Program at SAIC Frederick. Before that he was President and CEO of Structural GenomiX (later SGX Pharmaceuticals) of San Diego, a drug discovery company focused on cancer. Earlier in his career, Dr. Harris was Senior Vice President of Research at Sequana/Axys, where he expanded the research group from ten to over 200 people and secured four corporate deals. From 1989 to 1993, he was Director of Biotechnology at Glaxo Group Research in the United Kingdom, where he held responsibility for global high throughput screening. From 1981 until 1989, Dr. Harris was a senior molecular biologist at Celltech Ltd., a biotechnology company in the UK, cloning various genes coding for therapeutic proteins. Dr. Harris received a Ph.D. and M.S. in General Virology and a B.Sc. in Biochemistry from the University of Birmingham in England. Dr. Harris has an honorary doctorate (D.Sc) from the University of Birmingham, UK awarded in July 2010.

Elizabeth H. Hammond, MD

Elizabeth H. Hammond, MD

Currently, Dr. Elizabeth Hammond is a consulting pathologist with Intermountain Healthcare in Salt Lake City, Utah.  She is a trustee of the Intermountain Healthcare Research Foundation and previously served on the Intermountain Healthcare Governing Board. She also holds the position of professor of Pathology and adjunct professor of Internal Medicine at the University of Utah, School of Medicine in Salt Lake City.

Kevin C. Halling, MD, Ph.D.

Kevin C. Halling, MD, Ph.D.

Dr. Halling is an Associate Professor and the vice-chair of research and development in the Department of Laboratory Medicine and Pathology at the Mayo Clinic.  He directs the Clinical Molecular Genetics Laboratory and co-directs the Molecular Anatomic Pathology Laboratory.  He is boarded in Anatomic and Clinical Pathology, Clinical Molecular Genetics, and Molecular Genetic Pathology.  He is a past chair of the CAP Molecular Oncology Committee. Dr. Halling received his M.D. from the Kansas University School of Medicine and did his pathology residency at the Mayo Clinic.

Rolf Halden Ph.D., PE

Rolf Halden Ph.D., PE

Rolf is a Professor of Environmental Engineering, Founding Director of the Center for Environmental Security at Arizona State University, and also directs the proteomic mass spectrometry recharge facility for use by researchers within and outside of ASU’s Biodesign Institute. He has 20 years of experience in environmental exposure science and mass spectrometry.

Federico Goodsaid, Ph.D.

Federico Goodsaid, Ph.D.

Federico Goodsaid, Ph.D., is Vice President for Strategic Regulatory Intelligence at Vertex Pharmaceuticals. His work at Vertex is focused on early and effective interaction and collaborations on exploratory and product biomarkers with regulatory agencies. He was previously Associate Director for Operations in Genomics and Biomarker Qualification Coordinator at the Office of Clinical Pharmacology/Office of Translational Sciences/ Center for Drug Evaluation and Research/ U.S. FDA, working on the regulatory application and development of genomics and biomarkers at the FDA. His B.A.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS